These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 21366807)

  • 1. Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment.
    Wehrhan F; Hyckel P; Amann K; Ries J; Stockmann P; Schlegel K; Neukam F; Nkenke E
    Oral Dis; 2011 May; 17(4):433-42. PubMed ID: 21366807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of Msx-1 is suppressed in bisphosphonate associated osteonecrosis related jaw tissue-etiopathology considerations respecting jaw developmental biology-related unique features.
    Wehrhan F; Hyckel P; Ries J; Stockmann P; Nkenke E; Schlegel KA; Neukam FW; Amann K
    J Transl Med; 2010 Oct; 8():96. PubMed ID: 20942943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRONJ-related jaw bone is associated with increased Dlx-5 and suppressed osteopontin-implication in the site-specific alteration of angiogenesis and bone turnover by bisphosphonates.
    Wehrhan F; Amann K; Möbius P; Weber M; Preidl R; Ries J; Stockmann P
    Clin Oral Investig; 2015 Jul; 19(6):1289-98. PubMed ID: 25467232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
    J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
    Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?
    Reid IR; Bolland MJ; Grey AB
    Bone; 2007 Sep; 41(3):318-20. PubMed ID: 17572168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients.
    Favia G; Pilolli GP; Maiorano E
    J Rheumatol; 2009 Dec; 36(12):2780-7. PubMed ID: 19884275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
    Brown JJ; Ramalingam L; Zacharin MR
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):863-7. PubMed ID: 18221397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy.
    Favia G; Pilolli GP; Maiorano E
    Bone; 2009 Sep; 45(3):406-13. PubMed ID: 19450715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.
    Abu-Id MH; Warnke PH; Gottschalk J; Springer I; Wiltfang J; Acil Y; Russo PA; Kreusch T
    J Craniomaxillofac Surg; 2008 Mar; 36(2):95-103. PubMed ID: 18234504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonate-related osteonecrosis of the jaw.
    Feller L; Wood NH; Khammissa RA; Chikte UM; Bouckaert M; Lemmer J
    SADJ; 2011 Feb; 66(1):30-2. PubMed ID: 21510174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer.
    Van Poznak C
    Cancer Invest; 2006 Feb; 24(1):110-2. PubMed ID: 16467002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dental sinus tracts mimicking scrofuloderma: cutaneous presentation of underlying bisphosphonate-related osteonecrosis of the jaw.
    Kang HS; Lee JW; Kim JS
    Clin Exp Dermatol; 2011 Aug; 36(6):624-7. PubMed ID: 21771007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
    King AE; Umland EM
    Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dental and periodontal history of oncologic patients on parenteral bisphosphonates with or without osteonecrosis of the jaws: a pilot study.
    Carmagnola D; Celestino S; Abati S
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):e10-5. PubMed ID: 18801674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series.
    Freiberger JJ; Padilla-Burgos R; Chhoeu AH; Kraft KH; Boneta O; Moon RE; Piantadosi CA
    J Oral Maxillofac Surg; 2007 Jul; 65(7):1321-7. PubMed ID: 17577496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
    Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
    Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
    Mavrokokki T; Cheng A; Stein B; Goss A
    J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
    Estilo CL; Van Poznak CH; Wiliams T; Bohle GC; Lwin PT; Zhou Q; Riedel ER; Carlson DL; Schoder H; Farooki A; Fornier M; Halpern JL; Tunick SJ; Huryn JM
    Oncologist; 2008 Aug; 13(8):911-20. PubMed ID: 18695259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.